Compare GDC & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDC | CERS |
|---|---|---|
| Founded | 2015 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | EDP Services |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.3M | 276.0M |
| IPO Year | N/A | 1996 |
| Metric | GDC | CERS |
|---|---|---|
| Price | $2.76 | $1.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 35.5K | ★ 2.2M |
| Earning Date | 05-14-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $51,326,000.00 |
| Revenue This Year | N/A | $19.95 |
| Revenue Next Year | N/A | $8.84 |
| P/E Ratio | $7.47 | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $1.93 | $1.12 |
| 52 Week High | $9.92 | $2.96 |
| Indicator | GDC | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 33.76 | 39.36 |
| Support Level | $2.32 | $1.49 |
| Resistance Level | $3.72 | $1.78 |
| Average True Range (ATR) | 0.28 | 0.11 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 14.97 | 45.31 |
GD Culture Group Ltd focuses its business on two segments mainly through the Company and two subsidiaries. 1) AI-driven digital human creation and customization; 2) Live streaming and e-commerce. The company has relentlessly been focusing on serving its customers and creating value for them through the continual innovation and optimization of its products and services. For the AI-driven digital human creation and customization sector, the Company uses AI algorithms and software to generate realistic 3D or 2D digital human models. AI algorithms and machine learning models are used to simulate human characteristics, such as facial expressions, body movements, and even speech patterns.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.